Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KELLY GEORGE MCCAUL

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1295701522
CMS profile
194337
Location
SIOUX FALLS, SD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$114,551.44

114 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 3; records 1–50 of 114 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KELLY GEORGE MCCAUL

NPI 1295701522 · CMS profile ID 194337

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SIOUX FALLS, SD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 3; records 1–50 of 114 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295701522?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KELLY GEORGE MCCAUL, NPI 1295701522, CMS profile ID 194337. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 114 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295701522?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). KELLY GEORGE MCCAUL, NPI 1295701522, CMS profile ID 194337. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 114 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295701522?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
KELLY GEORGE MCCAUL, NPI 1295701522, CMS profile ID 194337, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 3; records 1–50 of 114 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1295701522?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

114 matching records · $114,551.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 114 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 114.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Incyte Corporation $685.0012/19/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141303571 CMS
Janssen Biotech, Inc. $26.1412/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078646395 CMS
Janssen Biotech, Inc. $825.0012/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078646119 CMS
Incyte Corporation $59.6212/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141246272 CMS
Kite Pharma, Inc. $123.4412/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128612757 CMS
Karyopharm Therapeutics Inc. $3,875.0012/03/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145532245 CMS
Karyopharm Therapeutics Inc. $0.9212/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145532249 CMS
Novartis Pharmaceuticals Corporation $33.2911/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087141094 CMS
Kite Pharma, Inc. $11.2611/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128612759 CMS
Incyte Corporation $604.7811/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141231209 CMS
Novartis Pharmaceuticals Corporation $18.8111/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087141090 CMS
Janssen Biotech, Inc. $3,575.0010/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078646506 CMS
Janssen Biotech, Inc. $73.5510/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078645878 CMS
PFIZER INC. $27.2610/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131379441 CMS
Takeda Pharmaceuticals U.S.A., Inc. $24.1510/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144962658 CMS
E.R. Squibb & Sons, L.L.C. $2,664.0010/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101418331 CMS
Karyopharm Therapeutics Inc. $1,550.0010/09/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145532241 CMS
Kite Pharma, Inc. $27.4709/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128612755 CMS
Janssen Biotech, Inc. $942.9709/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078645827 CMS
Genentech USA, Inc. $22.7709/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133046571 CMS
Janssen Biotech, Inc. $4,125.0009/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078646226 CMS
Janssen Biotech, Inc. $1,556.5809/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078646326 CMS
Janssen Biotech, Inc. $4,125.0009/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078646784 CMS
Janssen Biotech, Inc. $125.0009/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078646046 CMS
Karyopharm Therapeutics Inc. $1,550.0009/03/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145532233 CMS
Janssen Biotech, Inc. $22.5208/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078645910 CMS
Janssen Biotech, Inc. $550.0008/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078646450 CMS
Astellas Pharma US Inc $31.8008/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139402493 CMS
Mallinckrodt Hospital Products Inc. $2,325.0008/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145105511 CMS
Celgene Corporation $2.8008/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101133038 CMS
Kite Pharma, Inc. $12.4408/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128612751 CMS
Mallinckrodt Hospital Products Inc. $2,325.0008/13/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145105507 CMS
Janssen Biotech, Inc. $5.5008/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078646101 CMS
ADC Therapeutics America, Inc. $32.0408/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121192821 CMS
Janssen Biotech, Inc. $550.0008/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078646180 CMS
Karyopharm Therapeutics Inc. $1,550.0008/01/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145532224 CMS
Celgene Corporation $18.4707/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101133036 CMS
ABBVIE INC. $20.3707/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104995045 CMS
Karyopharm Therapeutics Inc. $5,425.0007/25/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145532253 CMS
Karyopharm Therapeutics Inc. $859.6207/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145532257 CMS
Karyopharm Therapeutics Inc. $10.4207/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145532262 CMS
E.R. Squibb & Sons, L.L.C. $2,664.0007/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101418309 CMS
Janssen Biotech, Inc. $21.4607/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078646146 CMS
E.R. Squibb & Sons, L.L.C. $2,854.0007/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101418295 CMS
Karyopharm Therapeutics Inc. $1,550.0007/11/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145532213 CMS
Celgene Corporation $20.8806/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101133032 CMS
Celgene Corporation $3.2606/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101133034 CMS
E.R. Squibb & Sons, L.L.C. $133.9106/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101418297 CMS
Janssen Biotech, Inc. $5.5006/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078646300 CMS
Novartis Pharmaceuticals Corporation $33.1206/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087141080 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $253,460.09 219
PY2020 $141,956.74 99
PY2021 $204,771.35 167
PY2022 $251,779.21 196
PY2023 $179,333.96 180
PY2024 $114,551.44 114
PY2025 $91,414.09 99

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $17,061.66 2
PY2022 Principal investigator $4,880.00 5
PY2021 Principal investigator $12,693.30 2
PY2020 Principal investigator $47,256.65 21
PY2019 Recipient $935.00 1
PY2019 Principal investigator $188,118.29 49

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 12/14/2020 Covered Recipient Teaching Hospital
Avera Mckennan
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL) No dispute reported 06/30/2026 719471529
Principal investigator 1 Celgene Corporation $211.70 11/28/2020 Covered Recipient Teaching Hospital
Avera Mckennan
A Multicenter, Single-Arm, Open-Label Treatment Us No dispute reported 06/30/2026 753808105
Principal investigator 1 Janssen Research & Development, LLC $750.00 11/20/2020 Covered Recipient Teaching Hospital
Avera Mckennan
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL) No dispute reported 06/30/2026 719471518
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 10/16/2020 Covered Recipient Teaching Hospital
Avera Mckennan
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL) No dispute reported 06/30/2026 719471509
Principal investigator 1 Incyte Corporation $500.00 09/30/2020 Covered Recipient Teaching Hospital
Avera Mckennan
Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome Myeloproliferative Neoplasm No dispute reported 06/30/2026 744320195
Principal investigator 1 Janssen Research & Development, LLC $589.00 09/14/2020 Covered Recipient Teaching Hospital
Avera Mckennan
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL) No dispute reported 06/30/2026 719471501
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 09/07/2020 Covered Recipient Teaching Hospital
Avera Mckennan
A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens No dispute reported 06/30/2026 719471533
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 07/27/2020 Covered Recipient Teaching Hospital
Avera Mckennan
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL) No dispute reported 06/30/2026 719471493
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,794.98 07/14/2020 Covered Recipient Teaching Hospital
AVERA MCKENNAN
AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (IRD) IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY RECEIVING A BORTEZOMIB-BASED INDUCTION REGIMEN (US MM-6) No dispute reported 06/30/2026 737060023
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,309.50 05/12/2020 Covered Recipient Teaching Hospital
AVERA MCKENNAN
AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (IRD) IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY RECEIVING A BORTEZOMIB-BASED INDUCTION REGIMEN (US MM-6) No dispute reported 06/30/2026 737060021
Principal investigator 1 Janssen Research & Development, LLC $91.00 04/17/2020 Covered Recipient Teaching Hospital
Avera Mckennan
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL) No dispute reported 06/30/2026 719471479
Principal investigator 1 Celgene Corporation $3,759.00 04/08/2020 Covered Recipient Teaching Hospital
Avera Mckennan
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 736443583
Principal investigator 1 Janssen Research & Development, LLC $89.00 04/06/2020 Covered Recipient Teaching Hospital
Avera Mckennan
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL) No dispute reported 06/30/2026 719471485
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $376.17 02/25/2020 Covered Recipient Teaching Hospital
AVERA MCKENNAN
AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (IRD) IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY RECEIVING A BORTEZOMIB-BASED INDUCTION REGIMEN (US MM-6) No dispute reported 06/30/2026 737060019
Principal investigator 1 Celgene Corporation $9,546.00 02/07/2020 Covered Recipient Teaching Hospital
Avera Mckennan
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) No dispute reported 06/30/2026 736443261
Principal investigator 1 Celgene Corporation $5,741.60 02/03/2020 Covered Recipient Teaching Hospital
Avera Mckennan
A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence No dispute reported 06/30/2026 736443251
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,674.50 01/28/2020 Covered Recipient Teaching Hospital
AVERA MCKENNAN
AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (IRD) IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY RECEIVING A BORTEZOMIB-BASED INDUCTION REGIMEN (US MM-6) No dispute reported 06/30/2026 737060017
Principal investigator 1 Incyte Corporation $7,021.80 01/22/2020 Covered Recipient Teaching Hospital
Avera Mckennan
Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome Myeloproliferative Neoplasm No dispute reported 06/30/2026 744320113
Principal investigator 1 Incyte Corporation $500.00 01/22/2020 Covered Recipient Teaching Hospital
Avera Mckennan
Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome Myeloproliferative Neoplasm No dispute reported 06/30/2026 744320115
Principal investigator 1 Celgene Corporation $82.74 01/14/2020 Non-covered Recipient Entity
Avera Cancer Institute Pharmacy
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) No dispute reported 06/30/2026 736451269
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $219.66 01/03/2020 Covered Recipient Teaching Hospital
AVERA MCKENNAN
AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (IRD) IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY RECEIVING A BORTEZOMIB-BASED INDUCTION REGIMEN (US MM-6) No dispute reported 06/30/2026 737060015